vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $134.9M, roughly 1.3× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 1.6%, a 80.9% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 5.0%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs -0.2%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CTRE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $177.4M |
| Net Profit | $111.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 82.5% | 1.6% |
| Revenue YoY | 55.1% | 5.0% |
| Net Profit YoY | 113.5% | — |
| EPS (diluted) | $0.52 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $134.9M | $196.9M | ||
| Q3 25 | $132.4M | $179.5M | ||
| Q2 25 | $112.5M | $181.1M | ||
| Q1 25 | $96.6M | $168.9M | ||
| Q4 24 | $86.9M | $187.3M | ||
| Q3 24 | $77.4M | $168.6M | ||
| Q2 24 | $68.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $5.4M | ||
| Q2 25 | $68.5M | $-4.8M | ||
| Q1 25 | $65.8M | $4.8M | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $-143.5M | ||
| Q2 24 | $10.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 58.1% | 3.5% | ||
| Q2 25 | 61.3% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 43.0% | -82.8% | ||
| Q2 24 | 15.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | 3.0% | ||
| Q2 25 | 60.9% | -2.7% | ||
| Q1 25 | 68.1% | 2.8% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | -85.1% | ||
| Q2 24 | 15.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.52 | $0.05 | ||
| Q3 25 | $0.35 | $0.12 | ||
| Q2 25 | $0.35 | $-0.11 | ||
| Q1 25 | $0.35 | $0.10 | ||
| Q4 24 | $0.30 | $0.38 | ||
| Q3 24 | $0.21 | $-3.11 | ||
| Q2 24 | $0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $144.3M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $653.9M |
| Total Assets | $5.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $198.0M | $238.4M | ||
| Q3 25 | $712.5M | $246.3M | ||
| Q2 25 | $306.1M | $445.9M | ||
| Q1 25 | $26.5M | $493.6M | ||
| Q4 24 | $213.8M | $484.6M | ||
| Q3 24 | $377.1M | $453.8M | ||
| Q2 24 | $495.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $894.2M | $372.2M | ||
| Q3 25 | $893.8M | $376.7M | ||
| Q2 25 | $1.2B | $580.5M | ||
| Q1 25 | $822.1M | $583.4M | ||
| Q4 24 | $396.9M | $585.3M | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $4.0B | $693.1M | ||
| Q3 25 | $4.0B | $727.2M | ||
| Q2 25 | $3.3B | $757.8M | ||
| Q1 25 | $2.9B | $798.5M | ||
| Q4 24 | $2.9B | $778.3M | ||
| Q3 24 | $2.4B | $749.6M | ||
| Q2 24 | $1.9B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.1B | $1.3B | ||
| Q3 25 | $5.1B | $1.3B | ||
| Q2 25 | $4.7B | $1.5B | ||
| Q1 25 | $3.9B | $1.6B | ||
| Q4 24 | $3.4B | $1.6B | ||
| Q3 24 | $2.9B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.22× | 0.54× | ||
| Q3 25 | 0.22× | 0.52× | ||
| Q2 25 | 0.35× | 0.77× | ||
| Q1 25 | 0.28× | 0.73× | ||
| Q4 24 | 0.14× | 0.75× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $394.0M | $43.7M | ||
| Q3 25 | $100.9M | $60.8M | ||
| Q2 25 | $100.8M | $12.0M | ||
| Q1 25 | $71.4M | $35.5M | ||
| Q4 24 | $244.3M | $33.1M | ||
| Q3 24 | $67.2M | $53.9M | ||
| Q2 24 | $53.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | 11.20× | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | 7.37× | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
